NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 195 participants.
Also called NCT01495364
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 195 participants
- Sponsor
- Lisata Therapeutics, Inc.
- Registry
-
NCT01495364
-
- Other papers using this trial's data
- PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01495364. Randomized; quadruple masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2014-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
- Acronym
- PreSERVE-AMI
- Condition
- ST Segment Elevation Myocardial Infarction
- Intervention (Biological)
- NBS10
- Intervention (Other)
- placebo
- Lead sponsor
- Lisata Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct01495364- Content hash
81e714eca4b3514370d9ccba6738aee97c5515dfa27c054607bb1e640dfb7f37